1 6 0 9 a r t i c l e s Myocardial infarction and other ischemic arterial diseases such as stroke typically result from an occlusive platelet thrombus that has formed at the site of a ruptured or eroded atherosclerotic plaque 1 . Thrombin is an especially potent physiologic agonist that mediates in vivo platelet activation. Human platelets express two thrombin receptors, protease activated receptors 1 (PAR1) and 4 (PAR4) 2 , both of which mediate thrombin signaling in platelets. During thrombininduced platelet activation, these receptors couple to specific G proteins, leading to activation of phospholipases and protein kinases, hydrolysis of phosphoinositides and increased amounts of cytoplasmic calcium 3 . Numerous differences in platelet activation have been characterized after stimulation of PAR1 or PAR4 (refs. 4-7). For example, compared to PAR1, PAR4 induces a more sustained rise in [Ca 2+ ] I (ref. 7) and is responsible for the majority of intracellular calcium flux. These observations suggest different kinetics of signaling and/or signaling pathways downstream of platelet PAR1 and PAR4.
a r t i c l e s
Myocardial infarction and other ischemic arterial diseases such as stroke typically result from an occlusive platelet thrombus that has formed at the site of a ruptured or eroded atherosclerotic plaque 1 . Thrombin is an especially potent physiologic agonist that mediates in vivo platelet activation. Human platelets express two thrombin receptors, protease activated receptors 1 (PAR1) and 4 (PAR4) 2 , both of which mediate thrombin signaling in platelets. During thrombininduced platelet activation, these receptors couple to specific G proteins, leading to activation of phospholipases and protein kinases, hydrolysis of phosphoinositides and increased amounts of cytoplasmic calcium 3 . Numerous differences in platelet activation have been characterized after stimulation of PAR1 or PAR4 (refs. 4-7) . For example, compared to PAR1, PAR4 induces a more sustained rise in [Ca 2+ ] I (ref. 7) and is responsible for the majority of intracellular calcium flux. These observations suggest different kinetics of signaling and/or signaling pathways downstream of platelet PAR1 and PAR4.
There is reproducible variation in platelet reactivity among different individuals, which likely contributes to thrombotic risk. The inter-individual variation in platelet reactivity is heritable 8 , and this heritability is greater in blacks than in whites 9 , but there is limited understanding of the genetic mechanisms that are responsible for this variability. Race is an independent predictor of survival in coronary heart disease even when demographic, socioeconomic and clinical factors are considered 10, 11 , suggesting that there are unidentified factors that account for this racial disparity. We hypothesized that a difference in platelet function may represent an important mechanism that accounts for some of the racial disparity in thrombotic risk. Human platelets offer a unique opportunity to assess the functional genomics of a primary cell in a relatively noninvasive and highthroughput manner because they can be obtained by sampling the peripheral blood. We designed the Platelet RNA And eXpression-1 (PRAX1) study to identify mRNAs and microRNAs (miRNAs) responsible for inter-individual variation in platelet reactivity using a cohort of 154 black or white healthy individuals. We discovered racial differences in platelet function and gene expression patterns that appear to contribute to this variation.
RESULTS

Enhanced PAR4-mediated platelet aggregation in blacks
We performed ex vivo platelet aggregation testing on platelets from 163 young, nondiabetic and generally healthy subjects. After exclusion because of use of anti-platelet medication or abnormal hematological parameters, we included 154 subjects for RNA profiling and analyses (Supplementary Table 1) . When comparing platelet a r t i c l e s 1 6 1 0 VOLUME 19 | NUMBER 12 | DECEMBER 2013 nature medicine function from the 70 black and 84 white subjects, we observed no racial difference in the average platelet maximal aggregation response to arachidonic acid, ADP, antibodies to CD9, collagen-related peptide or the PAR1 activation peptide (PAR1-AP), which activate platelets through the thromboxane, P2Y1-P2Y12, FcγRIIa, glycoprotein VI and PAR1 signaling receptors, respectively (Fig. 1a) . However, aggregation in response to PAR4-AP, which activates platelets through the PAR4 thrombin receptor, was higher in platelets from blacks compared to those from whites (3.8-fold higher at 50 µM PAR4-AP (P < 0.0001) and 1.4-fold higher at 75 µM PAR4-AP (P < 0.0001)) ( 7 5 0 a n t i-C D 9
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Self-identified whites Self-identified blacks Figure 1 Racial differences in PAR4-mediated platelet aggregation. (a) Maximal percentage aggregation (mean ± s.e.m.) of platelet-rich plasma samples from 70 black and 84 white subjects measured by light transmission aggregometry after stimulation with 500 µg ml −1 arachidonic acid (AA), 4 µM ADP, antibodies to CD9 (500, 750 or 2,000 ng ml −1 ), collagen-related peptide (CRP; 10 or 20 ng ml −1 ), PAR1-AP (1.0 or 2.5 µM) or PAR4-AP (50 or 75 µM). *P < 0.0001, two-sided MannWhitney for maximal percentage aggregation. (b) Time to 50% aggregation of washed platelets from black (n = 5) and white (n = 5) subjects after PAR4-dependent thrombin activation in the presence of 20 µM of the PAR1-specific antagonist BMS-200261 (BMS). P = 3.56 × 10 −5 , partial F statistic for race effect using two-way ANOVA (concentration and race). Error bars, s.e.m. The inset demonstrates the ability of 20 µM BMS to block maximally stimulated PAR1-induced but not PAR4-induced platelet aggregation using platelets from a normal donor. (c) PCA of 2 million genome-wide genotype markers in PRAX1 study subjects demonstrating that genotype strongly correlates with SIRE. Each circle represents a different individual. (ARS) that allows for precise differentiation among subjects with the same maximal aggregation (Online Methods), the racial difference in PAR4-mediated platelet aggregation was even stronger (P = 6.76 × 10 −9 ). Race was the dominant determinant of the PAR4 ARS when we considered differences in age, gender, body mass index (BMI) and platelet count (Supplementary Table 1 ) in a multiple linear regression analysis (P = 5.15 × 10 −8 , analysis of variance (ANOVA) partial F statistic of race for PAR ARS, normality of residuals checked by quantile-quantile plot).
To address the possibility that the platelet response to PAR4-AP does not accurately reflect the response to thrombin, the physiologic agonist of PAR4 and PAR1, we performed a detailed dose-response study using platelets from four blacks and three whites to assess racial differences in the platelet aggregation response to thrombin. When we restricted thrombin signaling to PAR4 by inhibiting PAR1 with BMS-200261 (ref. 12) , platelets from black subjects aggregated faster than platelets from white subjects at low concentrations of thrombin ( Supplementary Fig. 1b-e) . We observed no racial difference in maximal percentage aggregation when we used high concentrations of thrombin in the presence of the PAR1 inhibitor ( Supplementary  Fig. 1a-d) . Guided by the results of this thrombin dose-response study, we performed a replicate study with an additional five black and five white subjects. At low doses of thrombin (0.6-1 nM), platelets from black subjects again aggregated faster than those from white subjects in the in the presence of the PAR1 inhibitor (P = 3.56 × 10 −5 ) (Fig. 1b) .
Principal component analysis (PCA) applied to genome-wide genotyping data from the PRAX1 study subjects revealed two distinct and nonoverlapping groups that accounted for the largest variance. Superimposition of the self-identified race information onto the PCA results (Fig. 1c) indicated a 100% concordance. Taken together these data indicate a racial difference in human platelets that is specific to PAR4 signaling.
Platelet mRNAs are associated with PAR4 reactivity and race We prepared highly purified, leukocyte-depleted platelets (LDPs) from the PRAX1 study subjects by density centrifugation of citrated whole blood and then immunodepleted CD45 + leukocytes 13 . We profiled LDP mRNA using the Human Gene 1.0 ST Array (Affymetrix). On the basis of the distribution of the mean observed values, we selected a threshold for differentiating between commonly expressed and nonexpressed RNA: those reporters with values above the threshold were deemed commonly expressed, whereas those below the threshold were determined to be nonexpressed (Supplementary Fig. 2) .
Among the expressed transcripts reflecting more than 9,000 commonly expressed, annotated human genes, we identified 113 as being differentially expressed by PAR4 reactivity using a false discovery rate (FDR) q value cutoff of 0. 25 (ref. 14) , 93 of which correlated positively (Supplementary Table 3a ) and 20 of which correlated negatively (Supplementary Table 3b) . We found that 97 of the 113 (86%) PAR4-correlated transcripts were also differentially expressed between races, a much higher fraction than would be expected from the background rate of 30% differential expression by race among all platelet-expressed transcripts (odds ratio, 14.08; 95% confidence interval, 8.23-25.65; P = 2.58 × 10 −34 ) or the 36% differential expression by race found in a previous study 15 . Our analyses showed that racially divergent single-nucleotide polymorphisms (SNPs) occurring in the probe sequences on the Affymetrix Human Gene 1.0 ST Array were not responsible for the observed differentially expressed transcripts by race (Supplementary Fig. 3 ).
PC-TP and PAR4 reactivity
Because some of the 97 transcripts that were differentially expressed by race and PAR4 reactivity would be expected to be false positives, we performed Gene Ontology (GO) analysis using the Database for Annotation Visualization and Integrated Discovery (DAVID) (http:// david.abcc.ncifcrf.gov/home.jsp) as a guide for considering the most plausible true associations. Using the default settings and comparing to all assayed mRNAs on the Affymetrix Human Gene 1.0 ST array, we found mRNAs differentially expressed by PAR4 reactivity to be positively enriched in genes encoding proteins with phospholipid transporter activity (P = 8.0 × 10 −3 ), serine/threonine kinases (P = 4.4 × 10 −2 ) and proteins with pleckstrin homology domains (P = 2.9 × 10 −3 ). All of these functional categories are known to be relevant to platelet physiology. The gene encoding PC-TP (also called StARD2) 16 , PCTP, showed the strongest correlation with race (P = 10 −23 , q = 10 −20 ) and PAR4 reactivity (P = 3.4 × 10 −8 , q = 3.5 × 10 −4 ) (Supplementary Figure 3 Relationships among racial differences in PAR4 reactivity and transcripts. (a) Racial differences between 70 blacks and 84 whites for PAR4 reactivity, mRNAs and miRNAs, as shown in three heatmaps. Each column represents data from the same individual. Rows represent 93 mRNAs (middle heatmap) and 18 miRNAs (bottom heatmap) that are differentially expressed by race and that correlated with PAR4 reactivity. The vertical red bar indicates the strongly-correlated DLK1-DIO3-region miRNAs. (b) Network of miRNA-mRNA pairs that are differentially expressed by race and PAR4-mediated platelet aggregation. White and light blue fills distinguish miRNAs and mRNA, respectively. npg a r t i c l e s 1 6 1 2 VOLUME 19 | NUMBER 12 | DECEMBER 2013 nature medicine platelet function, and PC-TP is highly specific for binding phosphatidylcholine and catalyzes its transfer between membranes in vitro 16 .
Blacks had approximately fourfold higher expression of PCTP mRNA than whites (Fig. 2a) , and we confirmed this result by quantitative RT-PCR (qRT-PCR) ( Fig. 2b ) using samples that we selected to represent the extremes of the distribution, as well as samples representing intermediate levels. The Spearman rank correlation coefficient between the microarray and PCR data was 0.8263, which is within the normal validation range when comparing microarray and qRT-PCR data 17 . We also validated this racial difference by western immunoblotting of platelet lysates from all 70 black and 84 white subjects ( Fig. 2c,d ). In addition, we found a significant correlation between normalized PC-TP protein levels and reactivity to PAR4-AP among the PRAX1 samples (r = 0.249, P = 0.002, Pearson correlation).
Pctp has been knocked out in mice 18 , but we found that wild-type mouse platelets express little or no Pc-tp protein (Fig. 2e) , consistent with mouse platelet RNA data from a previous study 19 . Thus, we sought to test the function of this protein in human platelets.
Compound A1 (LDN-193,188), which has been identified as a smallmolecule inhibitor of the PC transfer activity of PC-TP 20 , displaces phosphatidylcholine from the lipid binding pocket and increases the thermal stability of the protein 21 . Incubation of human platelets with this specific PC-TP inhibitor prevented aggregation in response to PAR4-AP but not PAR1-AP (P = 0.016, two-sided t test) (Fig. 2f) . Calcium mobilization is a critical signaling event after platelet activation through PAR4. The megakaryocytic cell line Meg-01 mobilizes calcium in response to thrombin 22 , and, similarly to platelets, Meg-01 cells showed a more sustained PAR4-mediated intracellular calcium concentration response compared to the PAR1-mediated response (Fig. 2g) . Knockdown of PC-TP using siRNA blunted calcium release in response to PAR4-AP but not PAR1-AP (Fig. 2g,h ). In addition, compared to platelets from white subjects, platelets from black subjects showed a greater calcium mobilization in response to PAR4-AP (Fig. 2i) . These data demonstrate a role for PC-TP in PAR4-mediated calcium flux in platelets and are consistent with PC-TP-mediated racial differences in platelet aggregation.
The PCTP gene is targeted by miR-376c miRNA-mediated mRNA degradation is a potential mechanism for altering mRNA levels 23, 24 . Previous efforts at platelet miRNA profiling have utilized a small number of individuals and lacked data for PAR-mediated platelet activation 13, 25, 26 . We profiled the 154 PRAX1 platelet samples for miRNA levels and identified 178 miRNAs as being commonly expressed in human platelets using threshold criteria similar to those we used for mRNA ( Supplementary Fig. 2 ). Among the commonly expressed platelet miRNAs, we sought to identify those that are differentially expressed by race and that are predicted to target mRNAs that are also differentially expressed by race and PAR4 reactivity. As summarized in Figure 3a , we found that (i) the PAR4 response is higher in blacks than whites, (ii) expression of a set of mRNAs is elevated in blacks and positively correlates with the PAR4 response and (iii) expression of a set of miRNAs is decreased in blacks and negatively correlates with the PAR4 response. We also found a network of miRNA-mRNA pairs in which (i) both the miRNA and mRNA are differentially expressed by race, (ii) the levels of both the mRNA and miRNA correlate with PAR4-mediated platelet reactivity, (iii) the miRNA is predicted to target the mRNA and (iv) the miRNA and mRNA levels are inversely correlated (Fig. 3b) . Our analysis predicted that PCTP is targeted by miR-376c (Fig. 3b) , and we found that miR-376c levels were significantly inversely correlated with PCTP mRNA levels, PC-TP protein levels and PAR4 reactivity in the PRAX1 cohort ( Table 1) . Overexpression of miR-376c reduced PC-TP protein expression in the HCT human colorectal cancer cell line (Fig. 4a) and in the Meg-01 megakaryocytic cell line (Fig. 4b) , and reduced PCTP mRNA levels in Meg-01 cells and in the HEL megakaryocyte cell line (Fig. 4c) . Additionally, inhibition of miR-376c caused PCTP mRNA levels to rise (Fig. 4c) . Next, we isolated CD34 + hematopoietic stem cells from human cord blood and differentiated them into megakaryocytes and proplatelets (Fig. 4d,e) . Transfection of a miR-376c locked nucleic acid (LNA) inhibitor into CD34 + -derived CD61 + megakaryocytes increased PCTP mRNA levels by more than threefold, whereas overexpression of the miR-376c precursor decreased PCTP mRNA levels by 22% (Fig. 4f) . We determined the extent of miR-376c knockdown by the miR-376c LNA inhibitor and overexpression by the precursor ( Supplementary  Fig. 4) . Transfection with the LNA inhibitor had no effect on the expression level of a different miR-376 family member, miR-376b, or other miRNAs that are located within the same miRNA cluster, miR-410 and miR-495 (Supplementary Fig. 4 ). Reporter gene assays demonstrated the direct action of miR-376c on the wild-type PCTP 3′ untranslated region (UTR) but not a mutant PCTP 3′ UTR construct with a deleted miR-376c binding site (Fig. 4g) .
The DLK1-DIO3 miRNA cluster has higher expression in whites miR-376c is one of a set of miRNAs differentially expressed by race whose expression appears to be positively correlated with one another (Fig. 3a) . Indeed, expression analysis revealed a significant correlation among 24 of the 178 common platelet miRNAs, and all 24 mapped to chromosome 14q32.2 (Fig. 5a ). This locus is commonly called the DLK1-DIO3 genomic region and contains a large cluster of miRNA genes (Fig. 5b) .
A composite expression score that we generated for the miRNAs from this locus for each of the 154 subjects showed a strong association with race (black compared to white, P = 1.09 × 10 −5 ). When we included age, gender, BMI and platelet count in a multiple linear regression analysis, race remained the dominant determinant of miRNA expression in the DLK1-DIO3 region (P = 0.000166, partial F statistic). The expression of all commonly expressed DLK1-DIO3-region mature miRNAs (n = 24) was higher in whites than in blacks (Fig. 5c) . We also determined the commonly expressed miRNAs differentially expressed by race (Supplementary Table 4) and the Table 5 ). We confirmed racial differences in miRNA expression by qRT-PCR (Supplementary Fig. 5 ).
DLK1-DIO3-region
miRNA mean values, variances and P values by race (Supplementary
DISCUSSION
The richness of the PRAX1 data set provided unique opportunities to establish miRNA-mRNA-physiology relationships that led to a number of major findings. First, compared to platelets from whites, platelets from blacks showed greater reactivity in response to activation through the PAR4 thrombin receptor. Because PAR4 is expressed in tissues other than platelets (for example, the heart, brain and liver), these findings could be relevant for nonthrombotic diseases that are believed to show racial differences. Second, the newly identified platelet protein PC-TP mediates PAR4-dependent calcium mobilization and aggregation. Compared to platelets from whites, platelets from blacks expressed higher levels of PC-TP and had greater PAR4-dependent calcium mobilization and aggregation that in turn depends on PC-TP. Third, miR-376c regulated the expression of PC-TP in both megakaryocytes and megakaryocytic cell lines. Fourth, we discovered a genomic module of miRNAs and target mRNAs whose expression strongly correlates with the racial difference in PAR4-mediated platelet aggregation; many of these miRNAs clustered in the DLK1-DIO3 region and were expressed at higher levels in platelets from whites than from blacks. These findings should be considered in clinical trials involving anti-platelet therapies and ongoing drug development of inhibitors of protease-activated receptors.
There is a paucity of literature that considers racial differences in platelet function, and we are not aware of such work that has considered either thrombin receptors or explored associations between race and the platelet transcriptome. A single study reported that calcium mobilization varied by race in 46 patients with hypertension 27 , but it was unclear whether this difference was due to race or disease (hypertension), and the molecular mechanism responsible was not considered. We found that platelets from blacks demonstrated significantly greater activation to PAR4-AP than platelets from whites. Compared to tests of platelet function in response to thrombin, tests using PAR-activating peptides have the advantage of discriminating between PAR1 and PAR4 function and are amenable to the relatively high-throughput screening needed in the PRAX1 study. To address the possibility that there could be an unusual interaction between race and PAR4-AP-reactivity but not between race and thrombinreactivity (i.e., that the PAR4-AP response measured in this study does not reflect the true thrombin response), we performed two additional studies to assess thrombin-induced platelet aggregation under the condition of PAR1 inhibition, which verified that racial differences in PAR4-AP-reactivity reflected differences in the response to thrombin-activated PAR4. Although the data also suggest a possible racial difference in thrombin-induced platelet aggregation in the absence of the PAR1 inhibitor, this difference was less pronounced than in the presence of the PAR1 inhibitor, and a larger sample size would be needed to clarify this possibility.
Because the enhanced aggregation response in platelets from blacks was apparent only at the earliest time points and lowest thrombin concentrations, the racial difference in PAR4 reactivity may be primarily due to a difference in the kinetics of the response. Additional studies will be needed to determine whether there is a racial difference in the kinetics of the response to thrombin in the absence of PAR1 inhibition when both PAR1 and PAR4 are functional. The fact that we observed no racial difference for other platelet agonists strongly supports a relationship between race and PAR4-mediated platelet aggregation and argues against potentially confounding effects of other variables that could affect the readout of the assay, such as differences in integrin αIIbβ3 levels or in the level of a plasma protein affecting platelet aggregation. In this regard, plasma fibrinogen levels and von Willebrand factor (VWF) activity did not differ by race. Moreover, because we used washed platelets in the thrombin-response assays, the observed racial differences in reactivity are unlikely to be due to an unknown plasma cofactor or to an undiscovered protease that activates PAR4 but not PAR1. The racial difference in PAR4-AP-induced platelet aggregation was observed in separate cohorts from different cities (Houston and Philadelphia) with independent reagents, instrumentation and personnel.
Conclusions pertaining to race in this study raise issues regarding the recruitment strategy and our definitions of race. We recruited black and white subjects randomly throughout the duration of the study so that there was no chronological recruitment bias by race. Self-identified race and ethnicity (SIRE) has been shown to strongly correlate with selected genomic markers and ancient geographical ancestry [28] [29] [30] [31] . Moreover, we validated the use of SIRE in PRAX1 using PCA, which provides an unbiased examination of patterns within multilocus genotype data. American blacks are an admixed group 32 , and African lineages have greater diversity compared to American whites. Accordingly, there was a greater spread in the PCA representation of genotype data for individuals of self-reported African ancestry compared to individuals of self-reported European ancestry. Although the strong relationship between SIRE and genetic markers supports conclusions regarding a genetic effect on platelet function, it does not preclude a contribution of socioeconomic or environmental factors to variation in PAR4 reactivity.
Genome-wide gene expression analysis showed that more differentially expressed transcripts were positively associated with PAR4 reactivity than were negatively associated. Such asymmetry has been noted in other studies 33 . Perhaps the human platelet response mediated by PAR4 evolved in such a way as to promote blood clotting after trauma, providing a survival advantage; genetic drift is another possible explanation.
One hundred thirteen mRNAs (out of >9,000 expressed transcripts) were differentially expressed by both race and PAR4 reactivity. We pursued PCTP because of its strong statistical associations and its biological plausibility. PC-TP belongs to the steroidogenic acute regulatory transfer protein-related transfer (START)-domain superfamily, which constitutes a functionally diverse group of proteins that share a unique START domain for binding lipids 34 . PC-TP has been presumed to be expressed primarily in the liver, kidneys and testis 35 . PC-TP protein was not previously known to be present or function in platelets, although PCTP mRNA is one of a number of platelet mRNAs whose expression increases after hemodialysis in patients with chronic kidney disease 36 . In addition to catalyzing phosphatidylcholine transfer in vitro, PC-TP regulates both insulin and glucose metabolism in mice and human cell lines 16, 37, 38 , but the in vivo function of PC-TP in humans remains unclear. Phosphatidylcholine comprises a major fraction of platelet phospholipids, and multiple subcellular locations of phosphatidylcholine may exist 39 . Phosphatidylcholine is the classic substrate for phospholipase D, generating phosphatidic acid that can be converted to the second messenger diacylglycerol 40 . Phosphatidylcholine can also be hydrolyzed by phospholipase C to generate phosphatidylinositol 4,5-bisphosphate with subsequent release of calcium from intracellular stores. The PC-TP inhibitor, compound A1, blocked PAR4-induced but not PAR1-induced platelet aggregation, supporting a role for PC-TP in platelet function. Although it has been reported that A1 inhibits the closely PC-TPrelated proteins StARD7 and StARD10 (ref. 21 ), this inhibition is less effective. Furthermore, PCTP mRNA levels in platelets were 7.9-fold and 9.40-fold higher than the levels of STARD7 and STARD10 mRNA, respectively, according to our microarray data. These observations suggest that the predominant effect of A1 treatment on platelets is inhibition of PC-TP. The finding that A1 does not inhibit PAR1-dependent signaling suggests that PC-TP affects a signaling event that is downstream of PAR4 engagement but upstream of pathways shared by PAR1 and PAR4. Moreover, PC-TP depletion in megakaryocytic cells produced a functional effect on calcium mobilization that was PAR4 but not PAR1 dependent, supporting a role for PC-TP in regulating intracellular calcium transients and in contributing to the observed racial difference in PAR4-dependent calcium mobilization and platelet activation. The serine-threonine kinase encoded by AKT3 was also differentially expressed by race and PAR4 activation, consistent with the observation that Akt3 −/− mouse platelets lack responsiveness to thrombin but not other agonists 41 .
The DLK1-DIO3 region at the 14q32.2 locus is evolutionarily conserved and imprinted, harboring the DLK1 gene, the antisense RTL1 transcript, many small nucleolar RNAs (snoRNAs), long intergenic RNAs (lincRNAs), including MEG3, and the largest currently known cluster of miRNAs in the human genome (reviewed in ref. 42 ). The expression of some of the DLK1-DIO3 miRNAs has been associated with mouse stem cell pluripotency 43 and human cancer 42 , and a genetic locus contributing to paternally inherited type 1 diabetes has been mapped to this region 44 . The molecular mechanism for coordinate expression of human DLK1-DIO3-region miRNAs is unclear, although data in mice support processing of a single large transcript containing mature miRNAs 3′ to the snoRNAs cluster 45 , as well as individual transcriptional units 5′ of the snoRNAs cluster 46 . We note that our data do not exclude a role for lincRNAs or snoRNAs in regulating PAR4 function.
Our data demonstrate that miRNAs in this region are expressed at higher levels in platelets from white subjects than those from black subjects, and it will be important to assess other tissues and other RNAs encoded in this region for this racial difference. miR-376c, which resides within the DLK1-DIO3 region, was differentially expressed by race and PAR4-induced platelet reactivity and was predicted to target the 3′ UTR of PCTP. As might be expected if miR-376c targeting leads to PCTP mRNA degradation, miR-376c levels were inversely correlated with PC-TP mRNA and protein levels and were weakly correlated with PAR4-induced platelet aggregation. miR-376c directly reduced PCTP expression, as demonstrated by a series of overexpression, inhibition and binding site-mutation studies in a variety of cell types, including primary cultured human megakaryocytes. Figure 5d summarizes the proposed relationships identified in this study, emphasizing the effect of race on RNA expression that leads to racial differences in platelet PAR4 reactivity. Although there is a strong correlation between the platelet and megakaryocyte transcriptomes 47 , racial differences in platelet RNAs cannot be assumed to reflect differences that occur in megakaryocytes. Addressing this possibility would require a racially diverse source of progenitor cells. Nevertheless, transcriptomic and bioinformatic analyses of platelet RNA can guide experiments in cells to permit insights into relevant gene regulation in megakaryocytes.
There are clinical consequences to our findings, particularly in an era in which personalized medicine has been advanced as a strategy to improve patient outcomes. First, awareness and understanding of differences by which platelets are activated in blacks and whites is expected to aid in the ability to optimally treat these populations after myocardial infarction and stroke. Although the issue of race serving as a proxy for genetics in medical practice and research is controversial 48 , our results suggest that SIRE may have value in assessing hemostasisthrombosis risk in some populations. Anti-platelet therapy is a mainstay of managing coronary heart disease. However, there has been a notable absence or, at best, a poor representation of blacks in clinical trials of anti-platelet therapies and genome-wide association studies of atherothrombotic phenotypes. Unfortunately, neither cardiovascular trials with PAR1 inhibitors nor trials listed at clinicaltrials.gov allow the assessment of racial effects in clinical outcomes, and it is unknown whether racial differences in platelet reactivity affect the benefits and risks of these treatments. The PAR1 inhibitor vorapaxar is effective at preventing secondary atherothrombotic events but at the cost of increased bleeding [49] [50] [51] , and other new inhibitors of PAR1 and PAR4 are currently in clinical development 52 . In the presence of vorapaxar, PAR4 is the only means by which thrombin can activate platelets. Thus, it is critical to know whether the selection and dosing of such agents should be adjusted by race to maximize benefit and avoid toxicity. Our findings call for greater access to clinical trial data to address the effect of race on anti-platelet therapies. In addition, the racial differences in miRNA expression identified in the DLK1-DIO3 region may be present in other tissues, and more large-scale RNA studies can address this question. It will also be of interest to know whether PC-TP inhibition might be useful as an anti-thrombotic strategy, especially in disorders of altered glucose and insulin metabolism.
METhODS
Methods and any associated references are available in the online version of the paper.
Accession codes. The data discussed in this publication have been deposited in the NCBI Gene Expression Omnibus (GEO) and are accessible through GEO series accession number GSE49921. 
ONLINE METhODS
Subjects. The Institutional Review Boards of Thomas Jefferson University and Baylor College of Medicine approved the PRAX1 study, and we obtained informed consent from all volunteers. Only healthy, nondiabetic subjects who self-identified their race as white or black and were not using any anti-platelet medications were eligible for this study. We recruited black and white subjects randomly throughout the duration of the study. We recruited donors from 2010 to 2011 in Houston, Texas and in 2013 in Philadelphia, Pennsylvania and collected blood as previously described 53 .
Platelet function assessment. Houston studies. We obtained a complete blood count and mean platelet volume using an ABX Micros 60 CS (Horiba ABX, Irvine, CA, USA). Using light transmission aggregometry, we measured the maximal percentage aggregation and slope of aggregation at 10 min in plateletrich plasma treated with the following: 0.5 mg ml −1 arachidonic acid; 4 µM ADP; 500, 750 or 2,000 ng ml −1 antibodies to CD9 (Abcam, Cambridge, UK, ALB6); 10 or 20 ng ml −1 CRP (synthesized at Baylor College of Medicine and crosslinked with glutaraldehyde); 1 or 2 µM PAR1-AP (GL Biochem Shanghai, China); and 50 or 75 µM PAR4-AP (GL Biochem Shanghai, China).
Philadelphia studies. We used light transmission aggregometry of washed platelets to assess thrombin-induced platelet aggregation with or without a 2-min preincubation with 20 µM BMS-200261 (a PAR1-specific antagonist (a gift from S. Kunapuli, Temple University)) 12 . We observed a difference in the efficacy of the PAR1 inhibitor between the pilot and replicate studies but confirmed the PAR1-specific inhibitory activity in both studies (Fig. 1b and  Supplementary Fig. 1e ). For assessment of calcium mobilization, we recalcified platelets to a final concentration of 1 mM and then preincubated them with Fluo-4 AM (Invitrogen) for 10 min. We then stimulated platelets with PAR4-AP and measured calcium mobilization using the Accuri C6 flow cytometer 54 . In both the Houston and Philadelphia studies, we minimized technical variation by use of the same highly trained technicians, the same lots of reagents and the same instruments throughout the duration of the study.
Agonist response score. Because we used multiple concentrations to activate PAR1 and PAR4 to induce platelet aggregation, we developed an integrated score that combined these values to determine a single index that represented each individual's agonist response. We measured each subject in terms of maximum aggregation (Agg) and the kinetics (slope) of aggregation response versus time. Because we measured these two aspects of agonist response, as well as the response at different concentrations, we developed a single integrated score for each sample to represent the overall response to the agonist. For a single agonist concentration, the score we used is a weighted average of Agg and slope for the agonist response. This weighted average can be written as an equation: agonist response score (ARS) = w 1 × Agg + w 2 × slope, such that w 1 2 + w 2 2 =1
We used PCA to determine the weights that maximized variation across individuals for each agonist; both Agg and slope values were brought to a mean of 0 across subjects prior to PCA. The same scheme was used for multiple agonist concentrations, but additional weightings were determined by PCA across all slope and Agg values. To make the results more easily interpretable, the ARS scores were normalized back to the range 0,100 using a transformation in which the minimum was subtracted and the value was divided by the maximum score, yielding a value between 0 and 1. Multiplying by 100 determined the normalized value. This score correlated strongly with the standard assessment of maximal percentage aggregation, but our inclusion of slope (which was a minor contributor to the overall score and was highly related to maximal aggregation) allowed for distinguishing among platelets with the same maximal aggregation value (data not shown). This score was highly reproducible in ten subjects studied weekly for 3 or 4 weeks (data not shown).
Plasma assays. We measured plasma fibrinogen levels and VWF activity on an ACL TOP 500 (Instrumentation Laboratories, Bedford, MA) per the manufacturer's instructions. 54 . We monitored changes in intracellular Ca 2+ flux over time using an Accuri C6 flow cytometer.
Platelet mRNA profiling. We prepared LDP RNA by density centrifugation and immune depletion of CD45 + cells as previously described, yielding less than one contaminating leukocyte in 5 million platelets 13 . We extracted RNA with TRIzol (Life Technologies, Carlsbad, CA). We minimized technical variation by use of the same highly trained technicians, the same lots of reagents and the same instruments throughout the duration of the study. All RNA samples were subject to quality control screening using an Agilent Bioanalyzer. We labeled 300 ng of total LDP RNA and hybridized it to the Human Gene 1.0 ST Array (Affymetrix, Santa Clara, CA). For mRNA data preprocessing, we used the 'apt-probeset-summarize' option from the Affymetrix Power Tools for background subtraction, normalization and summarizing probeset values from the Affymetrix Gene array. We adjusted the background using the robust multiarray average technique. We background corrected the raw intensity values, log 2 transformed them and then quantile normalized them (the command line option was '-a rma-sketch'), similarly to our previous analysis 55 .
Platelet miRNA profiling. We performed digital miRNA profiling from 100 ng of total LDP RNA using the nCounter human miRNA assay kit v1 (NanoString Technologies, Seattle, WA) that counts miRNAs without amplification and produces high sensitivity and specificity, allowing for accurate comparisons of individual miRNA species within and between samples. In brief, a color-coded reporter probe and a capture probe are hybridized in solution to target molecules. The captured molecules are then attached to a streptavidin-coated slide and elongated and aligned by electrophoresis. The color-coded reporter probes are then counted. This technology has the advantages over standard microarray hybridization profiling of avoiding the biasing effects of RNA amplification and of direct measurement of the number of molecules detected and demonstrates linearity over 2.5 logs of concentration 56 . Total RNA was hybridized in solution to reporter probes labeled with fluorescent bar codes. Using capture probes, the software counted the hybridized miRNAs that adhered to a solid surface and the number of bar codes. We determined expression levels of well-characterized and validated human (n = 654) and human-associated viral (n = 80) miRNAs. To control for technical differences, we normalized the data using spike-in positive controls. To account for loading differences in miRNA content, we further normalized the data to the total number of miRNA counts in each sample. We set the background detection threshold as the average plus 2 s.d. of eight negative control probes. Notably, the values obtained in our data fell within the linearity of the NanoString assay.
Validation of RNA expression and miRNA knockdown. We cultured HCT116-Dicer knockout cell line in McCoy's 5A medium (Life Technologies, Carlsbad, CA) and the Meg-01 and HEL cells in RPMI medium (Life Technologies) adjusted to contain 10% (vol/vol) FBS. We seeded cells 24 h before transfection in six-well plates without antibiotics. To assess miR-376c knockdown of PC-TP, we transfected HCT115-Dicer knockout cells with 20-80 nM of pre-miR-376c (Life Technologies) or scrambled control (Life Technologies). We transfected Meg-01 and HEL cell lines with 100 nM of pre-miR-376c or the scrambled control, as well as the hsa-miR-376c miRCURY LNA microRNA inhibitor or miRCURY LNA microRNA inhibitor negative control npg (Exiqon, Denmark) using Lipofectamine LTX (Life Technologies) transfection agent following the manufacturer's protocol. After 6 h, we replaced the medium. We harvested HCT116-Dicer knockout cells 6, 24 and 48 h after transfection, and harvested Meg-01 and HEL cells 48 h after transfection. We isolated total RNA using TRIzol reagent (Ambion). To validate the relative expression levels of miRNAs and mRNAs, we performed qRT-PCR of PCTP transcripts with the Power SYBR Green PCR master mix (Life Technologies, Carlsbad, CA) using the primers 5′-AGAATGCAACGGAGAGACTGTGGT-3′ and 5′-TCACATGGATCTTCCTCCCTTCCA-3′ and normalized to β-actin mRNA. We quantified mature hsa-miR-376c, hsa-miR-376b, hsa-miR-410, hsamiR-495 and let-7b levels using TaqMan MicroRNA Reverse Transcription Kit and TaqMan MicroRNA assays together with TaqMan Universal PCR Master Mix, No AmpErase UNG (Applied Biosystems). We used the expression of miRNA RNU6B to normalize miRNA expression. We carried out real-time PCR reaction and analyses in 384-well optical reaction plates using the 7900HT instrument (Applied Biosystems). To confirm the effect of has-miR-376c on PCTP, we amplified the 3′ UTR of the PCTP gene from human genomic DNA with the primers, 5′-GAAACTAGTGGCAAGAGCCTGTCAGAACT-3′ and 5′-AGAACGCGTTGATGCACACTCACAAAAGG-3′, digested it with SpeI and MluI and cloned it into the pMIR-REPORT vector (Life Technologies). The predicted hsa-miR-376c target site was mutated using the QuikChange II XL Site-Directed Mutagenesis kit (Agilent Technologies, Santa Clara, CA) with the following primers: 5′-GGTAGGGTAAGGTATTCAAAGGCACAGCCTTG-3′ and 5′-CAAGGCTGTGCCTTTGAATACCTTACCCTACC-3′. Each vector was individually transfected into HEL cells along with the hsa-miR-376c precursor or a scrambled control. 48 h after transfection, extracts were harvested and analyzed for luciferase activity.
Western blotting and antibodies. We lysed LDPs and homogenized them in 8 M urea buffer (8 M urea in 10 mM Tris, pH 6.8, 1% SDS and 5 mM dithiothreitol in the presence of a 1× protein inhibitor mix (Roche, Indianapolis, IN)). We separated extracts by 12% SDS-PAGE and transferred them onto polyvinylidene difluoride membranes. We immunostained membranes with goat antibodies to human PC-TP (1:1,000, sc-23672, Santa Cruz Biotechnology, Dallas TX) 57 and mouse monoclonal antibodies to human GAPDH 58 (1:1,000, sc-25778, Santa Cruz). We performed detection and densitometric analysis with the Odyssey Infrared Imaging System (Li-Cor, Lincoln, NE). Protein extracts of HepG2 cells (ATCC, Manassas, VA), mouse platelets and mouse liver were made in RIPA buffer and separated as described above. Membranes were blotted with antibodies to tubulin (1:1,000, sc-5286, Santa Cruz) or PC-TP (1:1,000, sc-25778, Santa Cruz) antibodies.
Hematopoietic stem cell isolation and differentiation to megakaryocytes.
We obtained cord blood from the New York Blood Center, diluted it 1:2 with PBS and layered it over Histopaque (Sigma, St. Louis, MO). After 30 min of centrifugation at 400g, we carefully collected the buffy coat. We isolated CD34 + cells using magnetic immunoselection (Miltenyi Biotec, Auburn, CA) following the manufacturer's protocol. We then cultured cells at 4 × 10 5 cells per well in a 24-well plate with StemSpan medium (StemCell Technologies, Vancouver, Canada) supplemented with 25 ng ml −1 stem cell factor and 20 ng ml −1 thrombopoietin (TPO; Peprotech, Rocky Hill, NJ). After 6 d, we supplemented the cultures with 50 ng ml −1 TPO only. Every 3 d, we harvested the cells, counted and replated them at a density of 4 × 10 5 cells per well in a 24-well plate with fresh medium. We monitored megakaryocytic differentiation by flow cytometry, monitoring expression of CD34 (555821, BD Biosciences, San Jose, CA), CD41 (555466, BD Biosciences) and CD42 (IM1417U, Beckman Coulter, Indianapolis, IN). At 16 d, we seeded cells onto a fibrinogen-coated coverslip. We then stained cells with phalloidin-Alexa-533 (1:200, Life Technologies), rabbit antibodies to human tubulin 59 (1:200) and Alexa 488 F(ab′)2 goat anti-rabbit (1:200, A011070, Life Technologies). We then mounted the coverslips on slides using ProLong Gold Antifade Reagent with DAPI (Life Technologies). We captured images using a Zeiss LSM 510 Meta Confocal Laser Scanning Microscope with a META detector.
Statistical analyses.
Before performing the study, we performed sample size calculations using a linear model framework with Gaussian errors using effect sizes and variance estimates that were based on our previous work in which we performed genome-wide expression profiling with purified platelet samples 13, 25 . This effort indicated that 150 subjects would provide >85% power to detect modeled associations between platelet agonist phenotypes and RNA expression levels. For the continuous phenotype (response) data in this study, we used quantile-quantile plots to evaluate the normality of errors about linear model fits. For binary count data, we employed binomial sampling models and used Fisher's exact tests to evaluate associations, such as when testing the cross tabulation of those genes associated with PAR4 reactivity against those associated with selfidentified race. We did not find the variance of PAR4 reactivity within each race to be significantly different by an F test of the variances (F = 1.4; 95% confidence interval, 0.87-2.15; P = 0.2). We performed statistical analyses using the open source statistical programming environment R 60 . We performed association analyses between platelet PAR4 phenotype and gene expression using linear models. Multiple testing considerations were made using FDR methodology, and q values were estimated using the Benjamini-Hochberg method 61 as made available through the R function 'p.adjust' .
PCA. PCA is a commonly used mathematical approach that allows an unbiased examination of population structure in large-scale genotype data. PCA transforms high-dimensional multimarker genotypes encoded as reference allele counts from many subjects into simple, low-dimensional representations through projection to additive combinations of allele counts where the weights are the PCA loadings. This analysis permits identification of 'structure' such as race in the data. We applied this unbiased method to our samples. We extracted DNA from buffy coat preparations from all subjects in PRAX1 using the Gentra Puregene Blood Kit (Qiagen, The Netherlands). We hybridized DNA to the HumanOmni5 array (Illumnia Inc., San Diego, CA) at the Laboratory for Translational Genomics at the Baylor College of Medicine. We used the Eigenstrat software package 62 to compute the PCA transformation, excluding ethnicity information from the analysis.
Filters for detected and background probes. We excluded eight subjects for presumed anti-platelet medication use (defined as arachidonic acid aggregation of <30%), and one subject was excluded because of abnormal hematological parameters, leaving 154 samples for all subsequent analyses. In both the miRNA and mRNA data, we used a two-step filter to determine which probes to consider as expressed in our samples for the purposes of downstream analyses. We first used the distribution of the mean values for each probe across subjects to determine a cutoff that differentiated those features with background intensity from the others. We then counted the number of individual subjects with values that exceeded this background cutoff. The count distribution for the number of subjects exceeding the background cutoff was bimodal, indicating that most probes are either almost always expressed or almost never expressed in our cohort. To be considered commonly expressed, we therefore required that at least 100 subjects express the miRNA above background and that 115 subjects express the mRNA above background. For the mRNAs, we also required that the probeset was of the category 'main' as classified in the HuGene-1_0-st-v1.na33.2.hg19. transcript.csv file (available from http://www.affymetrix.com/support/technical/ annotationfilesmain.affx). A sensitivity analysis showed very little variation in the selected data based on small variations in the cut point for expressed RNAs, and the method was also robust to small variations in the percentage cutoff for the number of people expressing each RNA.
Exploratory analyses. We performed exploratory cluster analyses on the miRNA platelet expression data. Using Cluster 3.0, we centered and hierarchically clustered the normalized log 2 -transformed values of the 178 miRNAs that were above the cutoff (original software by Michael Eisen 63 , updated by Michiel de Hoon (University of Tokyo, http://bonsai.hgc.jp/~mdehoon/software/cluster/ software.htm)). We created a corresponding heatmap using Java Treeview. We calculated Pearson correlation coefficients pairwise for all 178 miRNAs above the cutoff using the R statistical package.
Model-based analyses. In addition to cluster analyses, we performed a series of correlative analyses to examine the associations between RNA expression and subject demographics, platelet agonist-induced aggregation and other hematological parameters. These analyses included simple and multiple linear regressions performed in R using analysis of variance (aov) tools that permit the evaluation of multiple explanatory variables. In the analysis of the PAR4 phenotype, we treated PAR4 reactivity as the dependent variable and included npg
